# Safety and Immunogenicity of FluLaval™ TR and Fluarix® (Influenza Vaccines) in Young and Older Adults

> **NCT00380211** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 660 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Influenza vaccine (A/H3N2, A/H1N1, and B strains)
- **BIOLOGICAL:** Fluarix

## Key facts

- **NCT ID:** NCT00380211
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** —
- **Final completion:** 2006-11
- **Target enrollment:** 660 (ACTUAL)
- **Last updated:** 2016-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00380211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00380211, "Safety and Immunogenicity of FluLaval™ TR and Fluarix® (Influenza Vaccines) in Young and Older Adults". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00380211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*